6 completed, 2 withdrawn, 1 active not recruiting, 1 no longer available. 4 Not applicable, 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 2, Suspended 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow Glucose Transporter Type 1 Deficiency Syndrome: new trials by email Literature Review of Glucose Transporter Type 1 Deficiency Syndrome trials Research Report on Glucose Transporter Type 1 Deficiency Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome Red Blood Cell Transfusion - Glucose Transporter Type 1 Deficiency Syndrome, GLUT1DS1 | Not applicable | Suspended | Weill Medical College of Cornell University | 12 | 2027-09-01 | 2025-12-11 |
| Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic Disease Magnetic resonance imaging - Glut1 Deficiency Syndrome 1, Glucose Metabolism Disorders | Recruiting | Weill Medical College of Cornell University | 20 | 2022-05-03 | 2026-06-01 | |
| Evaluation of Ketoflo Ketoflo - Epilepsy Intractable, Glucose Transporter Type 1 Deficiency Syndrome | Not applicable | Completed | Vitaflo International, Ltd | 25 | 2020-02-24 | 2024-02-15 |
| Early Check: Expanded Screening in Newborns Confirmatory Testing - Spinal Muscular Atrophy, Fragile X Syndrome | Active not recruiting | RTI International | 30000 | 2018-10-15 | 2026-07-01 | |
| Evaluation of Krio in Children and Adults With Epilepsy Krio - Ketogenic Dieting, Epilepsy | Not applicable | Withdrawn | Vitaflo International, Ltd | 2018-05-11 | 2024-02-16 | |
| Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) Triheptanoin - GLUT1DS1, Epilepsy | Phase 2 | Completed | University of Texas Southwestern Medical Center | 45 | 2018-04-18 | 2025-08-07 |
| Treatment Development of Triheptanoin (G1D) Triheptanoin - Epilepsy, GLUT1DS1 | Phase 1 | Completed | Juan Pascual | 12 | 2017-03-29 | 2022-12-22 |
| Evaluation of Keyo in Children With Epilepsy Keyo - Intractable Epilepsy, Glucose Transporter Type 1 Deficiency Syndrome | Not applicable | Completed | Vitaflo International, Ltd | 17 | 2016-04-01 | 2024-02-16 |
| Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) Triheptanoin - Glucose Transporter Type 1 Deficiency Syndrome, Glut1 Deficiency Syndrome | Phase 1 / Phase 2 | Withdrawn | Juan Pascual | 2015-12-01 | 2019-02-15 | |
| Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) UX007 - Glucose Transporter Type 1 Deficiency Syndrome | Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 15 | 2015-09-10 | 2020-06-11 |
| Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome Triheptanoin - Glucose Transporter Type 1 Deficiency Syndrome | Phase 2 | Unknown | University of British Columbia | 3 | 2014-04-01 | 2016-06-01 |
| The Glucose Transporter Type I Deficiency (G1D) Registry No intervention - GLUT1 Deficiency Syndrome, Glucose Transporter Type 1 Deficiency Syndrome | Completed | University of Texas Southwestern Medical Center | 471 | 2013-12-01 | 2025-03-07 | |
| Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) Triheptanoin - Glucose Transporter Type 1 Deficiency Syndrome, GLUT1 Deficiency Syndrome | Phase 1 | Completed | Juan Pascual | 14 | 2012-01-01 | 2019-10-31 |
| Post Study Continuation of C7 for G1D Triheptanoin - Glut1 Deficiency Syndrome, Glucose Transporter Type 1 Deficiency Syndrome | No longer available | Juan Pascual | 2019-04-18 |
Glut1 Deficiency Syndrome (14) · Epilepsy (6) · Glucose Metabolism Disorders (3) · Glycogen Storage Disease Id (3) · Drug Resistant Epilepsy (2) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1) · 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (1) · 3-methylcrotonyl CoA carboxylase 1 deficiency (1) · 3-methylcrotonyl CoA carboxylase 2 deficiency (1) · Acidemia, isovaleric (1) · Acrodermatitis enteropathica (1) · Adenine phosphoribosyltransferase deficiency (1) · Adrenal hyperplasia, congenital, type 5 (1) · Adrenocorticotropic hormone deficiency (1) · Amaurosis congenita of Leber, type 2 (1)
Brain Diseases (7) · Central Nervous System Diseases (7) · Nervous System Diseases (7) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Abnormalities, Multiple (1) · Albinism (1) · Albinism, Oculocutaneous (1) · Amino Acid Metabolism, Inborn Errors (1) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Arrhythmias, Cardiac (1)
triheptanoin (7) · Erythrocyte Transfusion (1) · Magnetic Resonance Imaging (1)
Juan Pascual (4) · Vitaflo International, Ltd (3) · University of Texas Southwestern Medical Center (2) · Weill Medical College of Cornell University (2) · RTI International (1) · Ultragenyx Pharmaceutical Inc (1) · University of British Columbia (1)
United States (10) · United Kingdom (3) · Australia (1) · Canada (1) · Denmark (1) · Spain (1)
Juan M. Pascual, MD, PhD (2) · Juan Pascual, MD, PhD (2) · Curt Scharfe, MD, PhD (1) · Helen McCullagh, BSc, MBChB (1) · Juan M Pascual, MD, PhD (1) · Juan Pascual (1) · Juan Pascual, MD (1) · Kathryn Lightfoot (1) · Rachel Meskell (1) · Sylvia Stockler (1)
PMID 31315600, PMID 35142618, PMID 36523131, PMID 36859467
R01NS094257 (2), RM1NS133593 (2), 2015 (1)